CAMBRIDGE, Massachusetts, November 8, 2018 Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter and nine-month 2018 financial results.
Company is Executing on Lead Programs CPI-1205 and CPI-0610 Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 recommended Phase 2 dose and begin the randomized portion of the trial in the fourth quarter of 2018.
We are excited about the progress we have made this year with our clinical programs and our entire epigenetics platform, said Jigar Raythatha, president and chief executive officer of Constellation Pharmaceuticals. In 2019, we look forward to further progress in our pipeline, as we expect to evaluate proof of concept for both our ProSTAR and MANIFEST clinical trials in mid-2019 as well as initiate clinical development of our second- generation EZH2 inhibitor CPI-0209. Recent News Continued enrollment in ProSTAR Phase 1b/2 study of CPI-1205 in metastatic castration-resistant prostate cancer (mCRPC). As planned, 34 sites are activated and enrolling patients in each of the two cohorts of the Phase 1b portion of the study. The Company expects to determine a Enhanced and expanded the Phase 2 portion of the ongoing MANIFEST study of CPI-0610 in myelofibrosis (MF). Constellation modified the MANIFEST trial design to stratify for transfusion-dependent status in second-line treatment and to initiate a first-line treatment arm in combination with ruxolitinib in JAK 1/2-inhibitor-naÃ¯ve patients with MF. These changes are intended to provide additional measures of potential clinical activity and to expand the potential addressable population of MF patients for CPI-0610, thereby enabling multiple potential paths to …
[Read on via official release]
Source: US SEC
View full document: EX-991_of_8-K_for_CONSTELLATION_PHARMACEUTICALS_INC__8-K-11-09-2018